Correlation between peripapillary atrophy and corticosteroid therapy in patients with Vogt-Koyanagi-Harada disease
- PMID: 16980924
- DOI: 10.1038/sj.eye.6702591
Correlation between peripapillary atrophy and corticosteroid therapy in patients with Vogt-Koyanagi-Harada disease
Abstract
Aims: To determine the correlation between systemic corticosteroid therapy and the occurrence and size of peripapillary atrophy (PPA) in patients with Vogt-Koyanagi-Harada (VKH) disease.
Methods: All patients with VKH disease were retrospectively reviewed for their corticosteroid regimen. The extent of the PPA, if present, was measured using digitized imaging software, by two masked observers. Eyes with myopia greater than 6 dioptres or glaucoma were excluded. The patients were classified into three groups: early high (EH), late high (LH), and low dose (LD), according to the dose and timing of corticosteroids received during the acute phase of the disease.
Results: There were 40 eyes in the EH group, 25 eyes in the LH group, and 23 eyes in the LD group. Multivariate analysis showed that corticosteroid therapy was the main determinant of PPA occurrence. All the eyes in the LD group had PPA and eyes in the LH groups were 4.02 times (95% confidence interval 1.24-13.07) more likely to develop PPA than those in the EH group. The LD group also had larger PPA to disc ratios than the EH group. (Mean of 2.83 vs0.19, P<0.001).
Conclusion: The development and extent of PPA in patients with VKH disease appear to be dependent on the dose and timing of systemic corticosteroids.
Similar articles
-
Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.Eye (Lond). 2009 Mar;23(3):543-8. doi: 10.1038/eye.2008.89. Epub 2008 Mar 28. Eye (Lond). 2009. PMID: 18369377
-
Choroidal thickness in convalescent vogt-koyanagi-harada disease.Retina. 2014 Apr;34(4):775-80. doi: 10.1097/IAE.0b013e3182a6b3f6. Retina. 2014. PMID: 23979311
-
Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease.Am J Ophthalmol. 2008 Mar;145(3):480-486. doi: 10.1016/j.ajo.2007.10.012. Epub 2008 Jan 11. Am J Ophthalmol. 2008. PMID: 18191100
-
Vogt-Koyanagi-Harada disease.Semin Ophthalmol. 2005 Jul-Sep;20(3):183-90. doi: 10.1080/08820530500232126. Semin Ophthalmol. 2005. PMID: 16282153 Review.
-
Vogt-koyanagi-harada syndrome.Curr Eye Res. 2008 Jul;33(7):517-23. doi: 10.1080/02713680802233968. Curr Eye Res. 2008. PMID: 18600484 Review.
Cited by
-
Prompt therapy reduces the duration of systemic corticosteroids in Vogt-Koyanagi-Harada disease.Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1641-2. doi: 10.1007/s00417-008-0869-5. Epub 2008 Jun 18. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 18563429 No abstract available.
-
The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1203-1211. doi: 10.1007/s00417-017-3654-5. Epub 2017 Apr 5. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28382438
-
miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.Front Cell Dev Biol. 2021 May 10;9:658514. doi: 10.3389/fcell.2021.658514. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34041239 Free PMC article. Review.
-
Vogt-Koyanagi-Harada Disease and COVID.J Clin Med. 2023 Sep 27;12(19):6242. doi: 10.3390/jcm12196242. J Clin Med. 2023. PMID: 37834885 Free PMC article. Review.
-
Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.Orphanet J Rare Dis. 2016 Mar 24;11:29. doi: 10.1186/s13023-016-0412-4. Orphanet J Rare Dis. 2016. PMID: 27008848 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials